The 5-HT 2C R agonist lorcaserin, clinically approved for the treatment of obesity, causes important side effects mainly related to subtype selectivity. In the search for 5-HT 2C R allosteric modulators as safer anti-obesity drugs, a chemical library from Vivia Biotech was screened using ExviTech® platform.
Obesity is a major risk factor for chronic diseases, such as diabetes, cardiovascular pathology, and certain cancers. 2 Hence, it is widely believed that obesity will become one of the leading causes of morbidity and mortality for this and future generations. Although a number of strategies have been used to tackle obesity, most of the marketed medicines have been withdrawn mainly due to safety issues, 3 including CNS-related adverse effects, and the pharmaceutical options available to obese patients are currently limited. 4, 5 Therefore, there is a major need for new agents that can provide a safe and effective mechanism for inducing weight loss.
Among the variety of pharmacological approaches that can be used to control body weight, the serotonin (5-hydroxytryptamine, 5-HT) system has long been known to be involved in the modulation of food intake. [6] [7] [8] Accordingly, classical anti-obesity medicines such as sibutramine (1) and (dex)fenfluramine (2) ( Figure 1A) act by increasing the level of serotonin. 6, 7 The current classification of the serotonin receptor family, which has essentially remained unchanged since 1994, [9] [10] [11] includes fourteen receptor subtypes classified into seven major classes (5-HT 1-7 ). The 5-HT 2 class comprises three GPCR members (5-HT 2A , 5-HT 2B , 5-HT 2C ) characterized by close sequence homology and coupling primarily via G q proteins to intracellular signalling pathways such as phospholipase C and phospholipase A. 12 In particular, serotonin 2C receptors are predominantly expressed in the CNS where they are widely distributed in different brain regions. There is substantial evidence supporting that their modulation may offer therapeutic benefit in various pathological conditions, including schizophrenia, substance addiction, and obesity. [13] [14] [15] Stimulation of 5-HT 2C Rs is the most advanced approach towards serotonin mediated control of food intake and associated reduction in body weight, and multiple research efforts have identified several promising 5-HT 2C R ligands. [18] [19] [20] In 2012, the 5-HT 2C R agonist lorcaserin (3, Figure 1B ) was approved by the FDA as a first-in-class anti-obesity drug. 21, 22 Therefore, the activation of 5-HT 2C Rs has been validated in the search of therapeutic strategies for the treatment of obesity. However, selectivity is critical because of the detrimental effects of 5-HT 2A and 5-HT 2B receptor activation that are respectively associated with potential hallucinogenic effects 23 and cardiac valvulopathy. 12, 24 Indeed, increased risk of cardiovascular and cardiopulmonary diseases has led to the withdrawal of non-selective serotoninergic drugs 1 and 2 from the EU and the USA markets, respectively, 25, 26 and certain restrictions apply to the use of compound 3 as its moderate 5-HT 2B R activity might induce major cardiac side effects. 27 Clearly, further efficacy and safety data are needed to prove the clinical utility of 5-HT 2C R ligands as anti-obesity agents.
In this context, the development of 5-HT 2C R agonists with better selectivity profiles for this worldwide disease would be of great value. This represents a significant challenge, as the molecular determinants involved in ligand recognition by 5-HT 2 R subtypes are highly conserved. 
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To date, PNU-69176E (4, Figure 1B ) is the only 5-HT 2C R PAM described, which was identified via screening of a chemical library of Pharmacia (now Pfizer). 32, 33 A derivative of this modulator (CYD-1-79, undisclosed structure) has recently been reported to potentiate 5-HT 2C R signalling in vivo in a drug discrimination assay, 34 though no anti-obesity properties have been described to our knowledge.
In the present work, we contribute to the quest for selectively acting 5-HT 2C R modulators. In the screening of a chemical library from Vivia Biotech company using a proprietary platform, compound 5 (VA240, Figure 2 ) was identified and validated as a moderate PAM of the 5-HT 2C R. Further structural modification in synthetic analogues 6-41 ( Figure 2 ) has led to compound 11 (VA012, N-[(1-benzyl-1H-indol-3-yl)methyl]pyridin-3-amine) with enhanced allosteric efficacy that was found to be very active in feeding models in rodents, reducing both food intake and body weight gain without inducing CNSrelated malaise.
RESULTS AND DISCUSSION
Hit identification: high-throughput screening. The proprietary ExviTech® platform developed by Vivia Biotech is a highly sensitive method based on flow cytometry to assess activation of GPCRs. A functional whole cell assay is used to access activity by measuring calcium mobilization in response to receptor activation. For screening, the tested compounds were added to HEK-293 cells stably expressing 5-HT 2C R, and after 10 min a 25% of the maximal effective concentration (EC 25 ) of serotonin was added.
The resulting percentage of cells that respond was then determined. The response for each well (i.e., compound) was compared to control receiving only an EC 25 Tables 1, 2) were generated by modification of the pyrimidine or the phenyl ring attached to the indole scaffold, respectively, to examine the effect on functional activity and allosteric modulation at the 5-HT 2C R. In compounds 6-14 (Table 1) , the phenyl ring was maintained and different nitrogen-containing heterocycles were introduced. These compounds were synthesized by reductive amination starting from 1-benzyl-1H-indole-3-carbaldehyde (Scheme 1). Derivatives 6-9 and 13 were prepared via one-pot reaction of the aldehyde with the corresponding pyrimidin-, pyrazin-, pyridazin-, or pyridinamine in 1,2-dichloroethane using sodium triacetoxyborohydride as reducing agent. For compounds 10-12 and 14, a two-step procedure was carried out. In this case, condensation of 1-benzyl-1H-indole-3-carbaldehyde with pyridazin-4-amine or the appropriate pyridinamine, catalyzed by ptoluenesulfonic acid in refluxing toluene, afforded the corresponding imine, which was isolated and subsequently reduced with sodium borohydride in methanol.
Synthesized compounds 6-14 were assessed for their effect on 5-HT-induced IP release in 5-HT 2C RHeLa cells. From the data in Table 1 , most compounds resulted inactive though in general pyridyl derivatives showed potentiation of the endogenous agonist effect. In particular, 3-pyridyl analogue 11 exhibited the highest potentiation (35% at 10 µM).
We next approached the synthesis of the second series of proposed compounds 15-41, where the 3-pyridyl moiety of compound 11 was maintained as N-heterocycle and the phenyl ring was modified. In analogues 15-37 (Table 2 ) substituents of different size and electronic effects (F, Cl, Br, Me, OMe, CF 3 , CN) were introduced in the benzene ring. These compounds were obtained by N-alkylation of the indole intermediate 42 with the appropriate benzyl bromide derivative using sodium hydride as base (Scheme 2). Intermediate 42 was prepared by reductive amination of 1H-indole-3-carbaldehyde with pyridin-3-amine, following the two-step procedure above described.
In addition, replacement of the benzene ring with a pyridine was considered in compounds 38-40, as well as that with a cyclopropane ring in compound 41 (Table 2) The new set of compounds 15-41 was tested in the IP functional assay and the data are shown in Table 2 . No substantial improvement of the allosteric potentiation was observed for any of the aryl derivatives, which exhibited lower values than unsubstituted analogue 11. The presence of heterocyclic pyridine or non-aromatic cyclopropane in analogues 38-41 was also less favourable than that of a phenyl ring (Table 2 ). Hence, compound 11 was selected for further pharmacological characterization as an allosteric modulator of the 5-HT 2C R. In addition to the selectivity exhibited over 5-HT 2 subtypes, no significant off-target agonist or antagonist activities were observed in a CEREP cellular GPCR profile of the compound (no effect over 20% at 10 µM was observed in either agonist or antagonist assays), which discarded important safety issues.
In radioligand binding competition assays, 10 µM 11 showed low displacement of the endogenous agonist (5-HT) or other orthosteric ligands (mesulergine and clozapine), suggesting its binding to a different site of the receptor ( Figure 3G ). The moderate affinity observed for compound 11 in the presence of LSD may be due to the location of this orthosteric ligand close to the extracellular domain of the receptor, where allosteric modulators of aminergic GPCRs bind.
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This is in agreement with the recently reported crystal structure of the closely related 5-HT 2B R bound to LSD. 35 Overall, the in vitro characterization of compound 11 proves its pharmacological profile as a specific and safe PAM of the 5-HT 2C R, which supports the exploration of its activity in vivo.
In vivo behaviour of the new 5-HT 2C R PAM 11. Prior to the evaluation of the new 5-HT 2C R PAM 11 in animal models, the in vivo brain permeability was studied ( Figure S1 ). Results showed a ratio of concentrations of the compound in brain and plasma of 3.8 after 120 min when administered intraperitoneally (i.p.) at a dose of 10 mg/kg. Importantly, this ratio was constant up to 6 h. These data prompted us to assess the behaviour of 11 in animal models of obesity.
In a first experiment, food intake was monitored upon acute administration of studied compound or the 5-HT 2C R agonist 47 (WAY 161503) 36 assayed as a reference compound of 5-HT 2C R activation ( Figures 4A and 4B ). Both compounds induced a reduction in feeding when they were acutely administered at 2 mg/kg (i.p.). Agonist 47 produced a reduction in food intake that was more intense at the earlier times and almost vanished after 4 h ( Figure 4A , dose effect F (2.80) = 51.9, P<0.01). Notably, the newly identified allosteric modulator 11 reduced feeding with a higher efficacy ( Figure 4B 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60 5.3, P<0.01), reaching almost 50% reduction after 4 h at the dose of 10 mg/kg. The effects of 11 were not related to the activation of serotonin 5-HT 2A R, as revealed by the persistence of food intake inhibition despite pretreatment with the 5-HT 2A R antagonist ketanserin ( Figure S2A ). In addition, the effect of 11 was not eliminated after pretreatment with the 5-HT 2C R antagonist 48 (SB-242084, Figure   S2B ), 37 whereas the antagonist did reduce the inhibition produced by the 5-HT 2C R agonist 47 ( Figure   S2C ). These results suggest no direct action of PAM 11 at the orthosteric site of the receptor.
When compound 11 was administered in a restricted food access model, it reduced both food intake Figure S3B ). The hypolocomotor profile of PAM 11 appears as a side effect that might limit its therapeutic utility at certain doses, as it has also been described for 5-HT 2C R agonists such as lorcaserin in animal models of obesity or nicotine addiction. 38 On the other hand, administration of compound 11 (2 mg/kg, i.p.) did not result in conditioned taste aversion ( Figure   4H , treatment per saccharin interaction, F (2.58) = 26.5, P<0.01), indicating that the compound did not cause malaise, in contrast to LiCl used as positive control.
As a way of demonstrating allosteric potentiation of serotonin-induced feeding suppression by compound 11, we tested the effects of co-administration with the selective serotonin re-uptake inhibitor (SSRI) sertraline. This antidepressant drug is known to induce a mild feeding suppression, as shown in 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60 sertraline ( Figure 5B ) and 2 mg/kg 11 with 5 mg/kg sertraline ( Figure 5C ). When the extracellular concentration of serotonin increased upon administration of sertraline, the anorectic effect of 11 was potentiated, as expected for a positive modulator of the receptor activity (interaction 11-sertraline F (9.111) = 4.6 P<0.001). This is a very remarkable action since the prevalence of depression associated to obesity is very high, i.e. 19% in severe obesity. 39 This combination might offer a new strategy for feeding reduction in depressed obese people.
CONCLUSIONS
In this work we have developed compound 11 (N-[(1-benzyl-1H-indol-3-yl)methyl]pyridin-3-amine)
as an allosteric modulator of the serotonin 5-HT 2C R that exhibits enhanced efficacy dose-dependently, no significant off-target activities, and low competition with the endogenous agonist or other orthosteric ligands. The compound was found to be very active in feeding models in rodents, reducing both food intake and body weight gain without causing CNS-related malaise when administered subchronically.
The effects were not related to 5-HT 2A R activation and a potentiation of the anorectic action of 11 was observed when administered in combination with sertraline, which suggests an allosteric modulation of serotonin effect in vivo. These results support the interest of a 5-HT 2C R PAM as a promising therapeutic approach for obesity.
EXPERIMENTAL SECTION
Synthesis. Unless otherwise stated, the starting materials, reagents, and solvents were purchased as high-grade commercial products from Sigma-Aldrich, Acros, ABCR, Fluorochem, Scharlab, or Panreac.
Analytical thin-layer chromatography (TLC) was run on Merck silica gel plates (Kieselgel 60 F-254), with detection by UV light (λ = 254 nm), 5% ninhydrin solution in ethanol or 10% phosphomolybdic acid solution in ethanol. Unless otherwise stated, products were purified by flash chromatography using a VARIAN 971-FP system with cartridges of silica gel (Varian, particle size 50 µm). All compounds were obtained as oils, except for those whose melting points (m.p.) are indicated, which were solids. 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58 General procedure for one-pot reductive amination. To a suspension of 1-benzyl-1H-indole-3-carbaldehyde (1.0 equiv) and NaBH(OAc) 3 (3.0 equiv) in anhydrous 1,2-dichloroethane (10 mL/mmol), the corresponding amino N-heterocycle (2.5 equiv) was added under an argon atmosphere and the reaction was refluxed for 8-15 h. After this time, the mixture was allowed to reach rt, and it was diluted with DCM and washed with water. The organic layer was dried over Na 2 SO 4 , filtered and concentrated. The crude was purified by flash chromatography (some of them were slurred with hexane afterwards) to afford the final compounds 6-9, 13. 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58 Data were normalized to 5-HT maximum effect and non-linear regression fitting was performed by using Prism v2.1 (GraphPad software).
N-[(1-Benzyl-1H-indol-3-yl)methyl]pyridazin-3-amine (9)
the All data are shown as mean±SEM of at least eight determinations per experimental group. KolmogorovSmirnov normality tests indicated that all data followed a Gaussian distribution (P > 0.1), so we selected a parametric statistical test. Differences between the treatments and time of testing (along 7-day testing) were analysed by two-way ANOVA for repeated measures, followed by exposed arms of the maze were measured. Test length was 5 min and animals were not retested (for details see Rodriguez de Fonseca et al. 2001 ).
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